Is vepotuzumab (POLIVY) a targeted drug?

The U.S. Food and Drug Administration(FDA) has approved an antibody-drug conjugate (ADC) to treat patients with diffuse largeB-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma in the United States. New drug velpotuzumab (POLIVY) is approved for use with the chemotherapy drug bendamustine and a rituximab product (a combination called "BR") to treat adults whose diffuse large B-cell lymphoma has worsened or has relapsed after at least 2 prior treatments.

Antibody-Drug Conjugate (ADC) Vepotuzumab is a targeted drug combined with chemotherapy. The targeted drug finds the cancer cell and then destroys it through chemotherapy. In this case, vepotuzumab attaches to a specific protein found on lymphoma patients' B cells and then releases its chemotherapy drug into those cells to kill the cancer. The recommended dose of vepotuzumab is 1.8 mg/kg.

Vepotolizumab's patent medicine has been launched in China. Due to its short time on the market, it has not yet entered the scope of medical insurance. It is an injectable preparation. The price of 30 mg per box may be around RMB 10,000. The price of the Hong Kong version of 140 mg per box may be around RMB 60,000 (the price may fluctuate due to exchange rates) overseas. The price of the European version of vepotuzumab on the market, Specifications140 mg per box, may be around 90,000 yuan (the price may fluctuate due to the exchange rate). The ingredients of domestic original drugs are basically the same as those of foreign original drugs, and they are expensive. There are currently no generic versions of vepotuzumab on the market.